Evidence map›Paper›PMID 41404183›Full record

ArticleFrontiers in health services2025

A harm-threshold model for ethical organ allocation.

Yan Jun Lin

Abstract read
In one paragraph

Article in Frontiers in health services, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yan Jun LinCornell University, College of Arts and Sciences, Ithaca, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Allocation of scarce donor organs must balance improving overall outcomes with protecting patients at greatest near-term risk. Urgency-focused systems such as MELD (Model for End-Stage Liver Disease) are efficient in saving lives but can reduce total post-transplant survival, whereas unconstrained utility maximization risks bypassing the sickest patients. Methods: We propose Harm-Threshold Utilitarianism (HTU), which maximizes expected post-transplant benefit subject to two guardrails: (i) an epistemic threshold requiring sufficient confidence before acting on predicted differences, and (ii) a catastrophic harm threshold that blocks bypassing candidates at high short-term waitlist mortality risk for only marginal or uncertain gains. Using de-identified U.S. liver transplant registry data, we performed proof-of-concept simulations of offer-like pools, comparing HTU with MELD-based selection. Outcomes included Kaplan-Meier curves and 5-year restricted mean survival time (RMST). Sensitivity analyses varied the harm threshold and confidence level. Results: HTU transparently reorders candidates relative to MELD while preserving alignment on broad priorities. In simulated pools, HTU-selected recipients achieved higher post-transplant survival; mean RMST improved by approximately 0.25 years per transplant (about three months) at baseline settings. Varying the catastrophic harm threshold produced a clear urgency-efficiency frontier: tighter thresholds selected more urgent patients with smaller gains, while looser thresholds increased gains but allowed more bypasses of urgent candidates. Conclusions: HTU operationalizes a tunable, ethically explicit trade-off between benefit and protection of the worst-off. By encoding precaution (confidence threshold) and a non-negotiable floor against catastrophic harm, HTU offers measurable efficiency gains without sacrificing fairness, and reframes policy choices as transparent parameters open to review.

Indexed as

decision theoryhealth policymedical ethicsMELDorgan allocationtransplantationutilitarianism

Identifiers

PMID41404183
PMCPMC12702880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.